Chronic inflammatory diseases: what they are and what they lead to
Rheumatoid arthritis, chronic inflammatory bowel diseases, such as ulcerative colitis and Crohns disease, psoriasis, and psoriatic arthritis, result in daily management of painful or disabling symptoms, impair patients quality of life, are a risk factor for the development of comorbidities, such as cardiovascular disease and cancer, and weigh on the lives of families, with major socioeconomic repercussions.
In recent years, attention to these diseases has increased, while Research has made enormous progress in understanding the mechanisms underlying acute and chronic inflammation and has led to the development of therapeutic options that can intervene in the inflammatory process.
The underlying mechanism of these diseases is inflammation, which must be evaluated by considering both the causes, including environmental ones, and the consequences on the whole organism, according to an integrated and multidisciplinary approach that privileges the continuity and interrelationships among different chronic inflammatory diseases.
Inflammation is a nonspecific innate defense mechanism, which is a protective response of the organism to the action of a damage operated by a foreign agent to eliminate the initial cause of cellular or tissue damage and the initiation of the reparative process inflammatory cells peculiar to innate immunity, such as macrophages, neutrophils begin to produce cytokines in response to a stimulus that can be infectious, chemical, non-infectious.
When acute inflammation does not resolve, chronic inflammation takes over, which consists of a long-lasting inflammatory process in which active inflammation, tissue destruction, and attempts at repair coexist.
Among the determinants of inflammation, attention has grown in recent years to the role played by the microbiota, the diverse set of microorganisms that live in symbiosis with us, in the gut but also in all surfaces exposed to the external environment.
A variation in the gut microbiota can result in inflammation that tends to spread from the gut to other organs.
A recent study carried out by Humanitas and published in the journal Science shows that in cases of ulcerative colitis, in order to prevent the spread of severe intestinal inflammation, the brain closes a kind of gate located in the choroid plexus, resulting in states of anxiety-like state and depression.
Effects often seen in patients with chronic inflammatory bowel disease.
There are more than 250,000 people living with chronic inflammatory bowel diseases in Italy, of whom about 60 percent have ulcerative colitis and the remaining 40 percent have Crohns disease.
These diseases, which are rapidly increasing in countries with advanced economies, manifest themselves mainly with diarrhea, often accompanied by traces of blood, abdominal pain, vomiting, asthenia, fever, and are characterized by alternating periods of flare-ups and periods of remission.
Up to 40% of patients with Crohns disease may undergo bowel resection within 10 years, and up to 20% of patients with ulcerative colitis may undergo colectomy within 10 years.
In more than 40% of cases, chronic inflammatory bowel disease is accompanied by associated extraintestinal immune-mediated manifestations.
Up to 30% of patients may have arthritis, 10% immune-mediated skin manifestations, and 5-6% biliary tract and liver inflammation.
Therefore, a multidisciplinary approach cannot be disregarded, leading to better outcomes in the detection of any associated extraintestinal manifestations, but also in their management.
The goal of therapy remains prolonged remission over time, which means absence of symptoms, both those directly reported by the patient and in terms of the anatomy of the disease, i.e., restoration of the normal integrity of the intestinal mucosa, without diarrhea and without bleeding.
One of the tools increasingly considered to induce remission is surgery, which for some patients with MICI is the best option.
By now, surgery is no longer considered as the only option, the last resort after exhausting the available options, when the patient was completely defecated by disease symptoms and non-response and immunosuppressed by medical therapies, with inevitable bad results.
Today, thanks in part to the multidisciplinary approach to chronic inflammatory bowel disease, which brings together the expertise of gastroenterologists and surgeons, surgery, which is increasingly less invasive, is a weapon that can be used at any point in the treatment pathway, depending on the needs of the individual patient.
Rheumatoid arthritis is characterized by its impact on quality of life: deformities and joint pain, if not adequately treated, can affect the patients ability to perform normal daily activities and limit work opportunities, even to the point of hindering the performance of household and family tasks.
The advent of new treatment options, however, has altered a course that until a few years ago seemed inescapable.
For patients diagnosed with rheumatoid arthritis today, there is a lot of good news: the most important element is that today the patients pathway does not lead to the deformities that can be seen on the web, thanks to biologic drugs and small molecules that are able to stop inflammation and thus disease progression and have collapsed the curve of surgeries to resolve these deformities.
But there are other positive notes as well: diagnoses are much earlier, thanks to increased knowledge and new diagnostic technologies; cortisone is used much less than in the past, sparing patients the medium- and long-term side effects; and patients of childbearing age can now plan a successful pregnancy by agreeing on the timing and synchronizing therapies so that they are not harmful to the fetus.
Inflammatory mechanisms, along with triggers such as infections, stress, and alterations in the microbiota, are at the root of immune-mediated skin diseases such as psoriasis, which affects about 2 million people in Italy, and psoriatic arthritis.
Psoriasis is a systemic disease in which the inflammatory process affects not only the skin, but also other districts and organs.
Especially at a young age, this disease is associated with an increased risk of acute cardiovascular events, and in 20-30% of cases patients with psoriasis may develop psoriatic arthritis.
In addition, subclinical intestinal inflammation can be found in patients with psoriasis, especially in the moderate-severe form, and 3% of patients with chronic inflammatory bowel disease also have psoriasis.
The link between intestinal and skin inflammatory processes is proven, and it is therefore essential that patients with immune-mediated diseases are evaluated from multiple perspectives and taken care of by a multidisciplinary team deputed to coordinate therapy and follow-up.
The professional medical figures who normally follow patients with psoriasis and psoriatic arthritis are the dermatologist and rheumatologist, but we also deal with the gastroenterologist, to significantly improve inflammation in the patient with Crohns disease and ulcerative colitis, thanks to combined therapies, which affect multiple areas by acting on a fundamental mechanism of pathogenic inflammation.
Emergency Live Even MoreLive: Download The New Free App Of Your Newspaper For IOS And Android
Crohns Disease: What It Is And How To Treat It
Psoriasis: What It Is And What To Do
Wales Bowel Surgery Death Rate Higher Than Expected
Irritable Bowel Syndrome (IBS): A Benign Condition To Keep Under Control
Colitis And Irritable Bowel Syndrome: What Is The Difference And How To Distinguish Between Them?
Irritable Bowel Syndrome: The Symptoms It Can Manifest Itself With
Chronic Inflammatory Bowel Disease: Symptoms And Treatment For Crohns Disease And Ulcerative Colitis
Crohns Disease Or Irritable Bowel Syndrome?
USA: FDA Approves Skyrizi To Treat Crohns Disease
Crohns Disease: What It Is, Triggers, Symptoms, Treatment And Diet
Gastrointestinal Bleeding: What It Is, How It Manifests Itself, How To Intervene
Faecal Calprotectin: Why This Test Is Performed And Which Values Are Normal
What Are Chronic Inflammatory Intestinal Diseases (IBD)?
Psoriasis, An Ageless Skin Disease
Psoriasis: It Gets Worse In Winter, But Its Not Just The Cold Thats To Blame
Childhood Psoriasis: What It Is, What The Symptoms Are And How To Treat It
Topical Treatments For Psoriasis: Recommended Over-The-Counter And Prescription Options
What Are The Different Types Of Psoriasis?
Phototherapy For The Treatment Of Psoriasis: What It Is And When It Is Needed
Humanitas
Link:
Chronic inflammatory diseases: what they are - Emergency Live International
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]
- Woman, 29, Slams Bullies Who 'Giggle And Whisper' At Her Unsightly Psoriasis Sores And Scabs, Leaving Her Depressed And 'Struggling To Walk' -... - August 15th, 2022 [August 15th, 2022]